Eduardas Aleknavičius

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.6K citations · Full text

Medicine, Pathology, Head And Neck Cancer +5

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2019 · 111 citations · Full text

Metastatic Breast Cancer, Breast Oncology, Medicine +7

A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients

Darius Norkus, Agata Karklelyte, Benedikt Engels et al. · Radiation Oncology · 2013 · 59 citations · Full text

Down-regulation of miRNA-148a and miRNA-625-3p in colorectal cancer is associated with tumor budding

Edita Baltruškevičienė, Diana Schveigert, Vaidotas Stankevičius et al. · BMC Cancer · 2017 · 47 citations · Full text

The value of prognostic factors for uterine cervical cancer patients treated with irradiation alone

Rūta Grigienė, Konstantinas Povilas Valuckas, Eduardas Aleknavičius et al. · BMC Cancer · 2007 · 39 citations · Full text